Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.

Related Keywords

Bristol Myers Squibb ,Abderrahim Oukessou ,Prescription Drug User Fee Act ,Blinded Independent Central Review ,Trial Evaluating ,Meets Primary Endpoint ,Progression Free Survival ,Mutated Locally Advanced ,Metastatic Non Small Cell ,Bristol Myers ,